Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

被引:1
|
作者
Silberg, Matteo [2 ]
Krabbe, Laura-Maria [3 ]
Boegemann, Martin [1 ]
Schrader, Andres Jan [1 ]
Tully, Karl [2 ]
Schlack, Katrin [1 ]
机构
[1] Univ Hosp Muenster, Dept Urol, Munster, Germany
[2] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Dept Urol, Hoelkeskampring 40, D-44625 Herne, Germany
[3] Vivantes Network Hlth, Dept Urol, Berlin, Germany
关键词
CRITERIA;
D O I
10.1016/j.clgc.2024.102164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Different combination therapies using anti - PD-1 / PD-L1 or CTLA-4 immune checkpoint inhibition (ICI) are widely used in patients with metastatic renal cell carcinoma (mRCC). In the absents of established biomarkers, immune-related adverse events (irAEs) have been discussed as potential predictors of response. Methods In this retrospective cohort study, data of 134 patients with mRCC undergoing ICI treatment (Nivolumab, Ipilimumab and Nivolumab, Pembrolizumab and Axitinib or Avelumab and Axitinib) between 2015 and 2021 were analyzed. To examine the utility of irAEs as predictors of overall survival (OS) and progression-free survival (PFS), separate Kaplan-Meier analyses and Cox proportional regression analyses were applied. Landmark analysis was conducted after 12 weeks to reduce immortal time bias. Result irAEs were observed in 85 patients (63.4%). Cutaneous (n = 52, 38.8%), endocrine (n = 33, 24.6%) and hepatic (n = 19, 14.2%) irAEs were most commonly observed. In Kaplan-Meier analysis, patients experiencing irAEs showed favorable median PFS (15 months, 95% CI, 9.91-20.09) compared to the non-irAE group (5 months, 95% CI, 3.56-6.44, P < .001). The median OS was 25 months (95% CI, 16.79-33.21) in the non-irAE group, while it was not reached in the irAE group (P = .002). In multivariable analysis, the presence of any irAE was associated with favorable PFS (HR 0.46 [95% CI, 0.26-0.82] P = .008) and OS (HR: 0.28 [95% CI, 0.12-0.63] P = .002), respectively. Landmark analysis after 12 weeks showed mixed results depending on the classification of the irAE group at the landmark time. Conclusion The presence of irAEs under ICI therapy in patients with mRCC is associated with better PFS and OS. Thus, manageable irAEs should not be cause for premature discontinuation of ICI therapy, as they seem to indicate favorable outcomes. Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).
    Abou Alaiwi, Sarah
    Martini, Dylan J.
    Xie, Wanling
    Nassar, Amin
    Bakouny, Ziad
    Steinharter, John A.
    Nuzzo, Pier Vitale
    Flippot, Ronan
    Chanza, Nieves M.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Bilen, Mehmet Asim
    Choueiri, Toni K.
    Harshman, Lauren Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [42] In the Clinic Immune-Related Adverse Events of Immune Checkpoint Inhibitors
    Ramos-Casals, Manuel
    Siso-Almirall, Antoni
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (02) : ITC17 - ITC32
  • [43] Immune-related adverse events of immune checkpoint inhibitors: a review
    Yin, Qinan
    Wu, Liuyun
    Han, Lizhu
    Zheng, Xingyue
    Tong, Rongsheng
    Li, Lian
    Bai, Lan
    Bian, Yuan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Daphne Day
    Aaron R. Hansen
    BioDrugs, 2016, 30 : 571 - 584
  • [45] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Day, Daphne
    Hansen, Aaron R.
    BIODRUGS, 2016, 30 (06) : 571 - 584
  • [46] Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?
    Peisen, Felix
    Gerken, Annika
    Hering, Alessa
    Dahm, Isabel
    Nikolaou, Konstantin
    Gatidis, Sergios
    Eigentler, Thomas K.
    Amaral, Teresa
    Moltz, Jan H.
    Othman, Ahmed E.
    CANCERS, 2024, 16 (15)
  • [47] IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS IN SPANISH PATIENTS
    Villalobos, L.
    Giraldo-sifuentes, W. A.
    Moran-alvarez, P.
    Arroyo Palomo, J.
    Briones-figueroa, A.
    Rita, C.
    Morell-hita, J. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 511 - 511
  • [48] Immune-related adverse events (IrAEs) in patients receiving immune checkpoint inhibitors
    Ferrarini, Alessia
    Benfaremo, Devis
    Rossetti, Giulia
    Morgese, Francesca
    Pomponio, Giovanni
    Berardi, Rossana
    Gabrielli, Armando
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [49] Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer
    Samanci, Nilay Sengul
    Cikman, Duygu Ilke
    Oruc, Kerem
    Bedir, Sahin
    Celik, Emir
    Degerli, Ezgi
    Derin, Sumeyra
    Demirelli, Fuat Hulusi
    Ozguroglu, Mustafa
    TUMORI JOURNAL, 2021, 107 (04): : 304 - 310
  • [50] Renal immune-related adverse events of immune checkpoint inhibitor
    Hu, Rongrong
    Chen, Minjiang
    Xu, Yan
    Wang, Mengzhao
    Zheng, Ke
    Li, Xuemei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 305 - 311